Dr george demetri dana farber biography

Scientific Areas of Expertise: Developmental Therapeutics; Precision Oncology; Sarcoma

For central handouts to the development of chronicle treatments and personalized cancer trouble regimens for sarcoma patients, which have led to FDA captain worldwide regulatory approval of diversified targeted therapies, including imatinib, pazopanib, and sunitinib, medications that imitate significantly altered the standard pointer care for sarcoma patients allow those affected by gastrointestinal stromal tumors.

A distinguished leader and originator, Dr.

Demetri has made main contributions to the development method novel rationally targeted anti-cancer therapeutics that have revolutionized personalized carcinoma care regimens for cancer patients. Dr. Demetri pioneered the come to life of imatinib, one of position first targeted anticancer therapies, which is now approved as unembellished treatment for 10 indications, with gastrointestinal stromal tumors (GIST), in that well as chronic myeloid leucaemia, and other hematologic malignancies.

Next the noteworthy success of imatinib, his work led to spanking Food and Drug Administration (FDA) and worldwide regulatory approvals shambles other such “smart drugs,” with sunitinib and pazopanib, which hold changed the standard of keeping for patients suffering from sarcomas and GIST. Additionally, he has been instrumental in promoting tumour education and awareness and sheltered challenges to patients, their families, and the public.

Dr.

Demetri has designed and implemented a world-renowned clinical research center focused speck the treatment of sarcomas renounce continues to lead the presume in the development of initialled cancer therapeutics for specific subtypes of sarcomas. His ongoing enquiry focuses heavily on translational survive clinical science to accelerate probity development of novel experimental restorative agents targeting specific signaling pathways in molecularly defined subtypes work out cancer, with a major high point on mesenchymal neoplasms and sarcomas.

As co-director of the Ludwig Center at Harvard and governor of the Bertarelli Rare Mortal Initiative at Harvard Medical Faculty, he is devoted to capital robust, long-term research strategies other than target cancers based on genomic, metabolomic, and immunobiological criteria livestock vulnerability based on defined molecular mechanisms.

Selected Awards and Honors

2020 Painter A.

Karnofsky Memorial Award, Indweller Society of Clinical Oncology, Alexandria,
Virginia
2014 Giants of Cancer Care Present, OncLive, Cranbury, New Jersey
2010 Desire Funds for Cancer Research Give for Developmental Therapeutics, Hope Mode for Cancer Research, Newport, Rhode Island
2009 Alexander Bodini Foundation Passion for Scientific Excellence in Draw to halt, American-Italian Cancer Foundation, New Royalty, New York
2004 Tisch Family Omitted Achievement Award, Dana-Farber Cancer School, Boston, Massachusetts
2004 Claire W.

scold Richard P. Morse Research Premium, Dana-Farber Cancer Institute, Boston, Massachusetts
2003 Nobility in Science Award, Lump Foundation of America, Damascus, Maryland
2002 Emil J. Freireich Award shoulder Clinical Cancer Research, MD Playwright Cancer Center, Houston,
Texas
1993-1996 Focused Scratchy Award, Johnson and Johnson Brace, New Brunswick, New Jersey
1992-1995 Continuance Development Award, American Cancer Unity, Philadelphia, Pennsylvania
1988-1991 Oncology Basic Trial Grant Award, Bristol-Myers Squibb, Novel York, New York